Investment in Disruptive Biotech Ventures

The Stanford Club of France & ReedSmith present:


How to make the most from investment cycles in disruptive Biotech ventures? 


What are the innovative ways for developing and for financing emerging Biotech ventures?


Join the Stanford Club of France, sponsored by Reed Smith, for a roundtable and networking session on discovering the development phases, growth models and financing challenges for the life science companies.


Our guest experts will share their insights on:




  1. Key Success factors in the firm’s Development & Growth Phases




  2. Financing from inception to growth to IPO: Capital structure evolution and its implications




  3. Searching for financing: Financing in US vs Europe






ABOUT THE SPEAKERS:


 


Karen Aiach


CEO, Lysogene


Founder and CEO of Lysogene, Ms. Aiach is also the mother of a child with MPS IIIA. She has a strong business background starting her career with Arthur Andersen specializing in audit and transaction services. Her entrepreneurial experience includes founding and running a financial business consultancy. From 2008 to 2009, Ms. Aiach served as a Member of the Pediatric Committee at the European Medicines Agency (EMA), established in accordance with the European Pediatric Regulation, as a patient representative. In 2008, she also served on the French Ethical Review Board CCPPRB at Ambroise Paré Hospital.  Ms. Aiach has been involved with several not-for-profit organizations engaged in advocacy and research in the field of rare diseases such as Alliance Sanfilippo and Eurordis, where she served on the board as treasurer from 2010 to 2011. She is a founding executive member of the International Rare Diseases Research Consortium (IRDiRC).


Ms. Aiach graduated from the ESSEC Business School and majored in Economics.


 



Rodolphe Besserve


Director Corporate Finance Healthcare – Société Générale


Director in Biotech / Medtech Corporate Finance


Executed more than 30 deals over the last 5 years (IPOs, right issues, private placements, M&A transactions)


Former Research Analyst and opinion leader in the Biotech / Medtech sector (10 years of experience)


6 years as Head of Biotech Research at Société Générale


Prior to joing Société Générale, Rodolphe worked for Kepler Equities and Bryan Garnier, as Head of Mid-cap and Big Pharma coverage


Rodolphe has a chemical engineering background and graduated from EM Lyon in Finance


 



André Choulika


CEO, Cellectis


Dr. André Choulika, Ph.D. is the Founder of Cellectis SA and has been its Chief Executive Officer since 1999 and as its Chairman since June 27, 2011. Dr. Choulika is a pioneer in the analysis and use of Meganucleases to modify complex genomes. Dr. Choulika has made many of the critical observations in the field and is an author of the most significant patents on the use of Meganucleases in vivo. He has been Chairman of Calyxt, Inc. since August 2010. He serves as the Chairman of France Biotech. He serves as a Director of Cellectis SA. Dr. Choulika is a Member of Investment Committee at G1J Ile-de-France SA, SCR. He received a Ph.D. in Molecular Virology from the University of Paris VI / Institut Pasteur. Dr. Choulika has made post-doctoral studies at the Harvard Medical School within the department of Molecular Medicine of Boston’s Children’s Hospital.


  



Pierre-Louis Périn


Partner, Reed Smith


Pierre-Louis Périn is partner in the Corporate Department of Reed Smith in Paris.


He specialises in Venture Capital and advises on investments in private equity funds and on the structuring of private equity management companies. He also has expertise in corporate governance, incentives schemes, shareholder disputes, as well as in M&A (domestic and international) and joint ventures.


Pierre-Louis is an associate professor at Sciences Po Paris and he has been an active member of AFIC (French Venture Capital Association)’s commissions on venture capital, ethics and training. Pierre-Louis is a graduate of Sciences Po Paris and holds a Law PHD from University Paris II – Panthéon Assas.


After ten years in the legal departments of financial and industrial groups, Pierre-Louis became a lawyer and is a member of the Paris bar since 1997. He joined King & Wood Mallesons (then SJ Berwin) as a partner in 2001.


The discussion will be followed by a networking session in an informal setting with Stanford Alumni and other professionals from the life sciences and health industry.





Evelyne Nguyen – Moderator


CEO, ANMPARTNERS


Board member of the Stanford Club of France


Evelyne graduated from ISG (Institut Supérieur de Gestion) and Stanford (SEP 2003).


She formerly held CFO – SVP Finance & Strategy responsibilities, then EVP Biomanufacturing capacities at LFB then founded ANMPartners in 2013.  a Finance, Strategy and Business Development advisory firm dedicated to Healthcare industries.


Evelyne’s track record includes M&As, strategic project management and financing.


As a member of SCF Board since 2012, she served as Treasurer from 2012 to 2014 and currently active in corporate events related to Asia and Pharma/Biotech sectors.


Evelyne key role is to develop SCF relations with private & public companies and corporate organizations.

Date and time

September 11, 2018, 8:00 AM - 10:30 AM

Location

ReedSmith - Centre d’Affaires Paris Trocadéro
112 Avenue Kléber
75116 Paris